GSK shares jumped ... claims its Zantac heartburn drug causes cancer. The Delaware Supreme Court said it will review a decision by a lower court to let an upcoming trial hear evidence from ...
GSK plc (LSE/NYSE: GSK), a leading global pharmaceutical company, has reached a confidential settlement in a Zantac (ranitidine ... objective in the phase II trial. TD Cowen maintained a Hold ...
Delaware’s top court is set to hear an appeal from GSK and other pharmaceutical ... In December 2022, approximately 50,000 Zantac cases were dismissed during a pre-trial hearing in Florida.
Aug 27 (Reuters) - Delaware's highest court said on Tuesday it will hear an appeal by GSK (GSK.L), opens ... heartburn drug Zantac caused cancer. There has been no trial or final judgment in ...
At 4:31 am (0831 GMT), GSK was trading 1.5% higher at £1,642.11. The litigation at the center of this legal battle revolves around allegations that ranitidine, the active ingredient in Zantac ...
GSK Plc’s experimental vaccine for herpes failed in an early-stage trial, halting an effort to bring the first shot for the condition to market. While there were no safety concerns, the trial ...
Sept 11 (Reuters) - British drugmaker GSK (GSK.L), opens new tab said on Wednesday its experimental herpes simplex virus (HSV) vaccine candidate failed to meet the main goal of a mid-stage trial ...
(RTTNews) - GSK plc (GSK, GSK.L) announced positive headline results of MATINEE, the phase III clinical trial evaluating Nucala (mepolizumab), a monoclonal antibody that targets interleukin-5 (IL ...
GSK has announced that Part II of the Phase I/II TH HSV REC-003 trial of its therapeutic herpes simplex virus (HSV) vaccine candidate, GSK3943104, did not meet its primary efficacy endpoint.
GSK plc (LSE/NYSE: LON:GSK), a leading global pharmaceutical company, has reached a confidential settlement in a Zantac (ranitidine ... to meet the primary efficacy objective in the phase II trial. TD ...
GSK’s (NYSE:GSK) investigational herpes simplex virus (HSV) vaccine candidate failed to meet the primary goal of a mid-stage trial and will not progress to a late-stage trial. The British ...
